<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414255</url>
  </required_header>
  <id_info>
    <org_study_id>AIAT001</org_study_id>
    <nct_id>NCT03414255</nct_id>
  </id_info>
  <brief_title>Micronized dHACM Injectable for the Treatment of Achille Tendonitis</brief_title>
  <official_title>A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial Of The Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Achilles Tendonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as&#xD;
      Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 158 subjects will be enrolled in this study. Each patient will receive 1&#xD;
      injection and be evaluated for efficacy and safety during a 12 month observation period.&#xD;
      Randomization will be 1:1. The study is expected to be completed in 24 months, inclusive of&#xD;
      enrollment and follow-up of all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS score</measure>
    <time_frame>90 days</time_frame>
    <description>Visual Analog Scale, Left end point is &quot;No Pain&quot;. Right end point is &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>365 days</time_frame>
    <description>The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foot Function Index Revised (FFI-R) (Short Form)</measure>
    <time_frame>90 days</time_frame>
    <description>Subjects circle the number that correlates how bad their foot pain was in certain situation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Tendonitis;Achilles</condition>
  <arm_group>
    <arm_group_label>Micronized DHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Micronized DHACM</intervention_name>
    <description>1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).</description>
    <arm_group_label>Micronized DHACM</arm_group_label>
    <other_name>dHACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Injection</intervention_name>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Saline Injection</arm_group_label>
    <other_name>0.9% NaCL</other_name>
    <other_name>Normal Saline</other_name>
    <other_name>Sodium Chloride Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        All subjects enrolled must meet all the following criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of Achilles tendonitis for ≥ 1 month (30 days) and ≤ 18 months by&#xD;
             the investigator&#xD;
&#xD;
          2. VAS Pain scale of ≥ 45 at randomization&#xD;
&#xD;
          3. Achilles Tendonitis with conservative treatment for ≥1 month (30 days) while under the&#xD;
             direction of the healthcare provider, including any of the following modalities:&#xD;
&#xD;
               -  Rest, Ice, Compression, Elevation (RICE)&#xD;
&#xD;
               -  Stretching exercises&#xD;
&#xD;
               -  Nonsteroidal Anti-inflammatory Drugs (NSAIDs)&#xD;
&#xD;
               -  Orthotics&#xD;
&#xD;
          4. Diagnostic AP and lateral X-Ray within 6 months of enrollment showing view of&#xD;
             calcaneus negative for calcaneal fracture or structural abnormalities&#xD;
&#xD;
          5. BMI ≤ 40 kg/m2&#xD;
&#xD;
          6. Age from 21 to 80 years&#xD;
&#xD;
          7. Ability to sign Informed Consent and Release of Medical Information Forms&#xD;
&#xD;
          8. Ability to receive and respond to text messages or emails on a daily basis.&#xD;
&#xD;
        Exclusion Criteria Any potential subjects meeting any of the following criteria will be&#xD;
        excluded from enrollment and subsequent randomization.&#xD;
&#xD;
          1. Prior surgery to the affected site.&#xD;
&#xD;
          2. Subjects requiring bilateral Achilles tendonitis treatment at time of enrollment&#xD;
&#xD;
          3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in&#xD;
             either limb within the last 3 months&#xD;
&#xD;
          4. Has diabetes either Type I or Type II&#xD;
&#xD;
          5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone&#xD;
             attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.&#xD;
&#xD;
          6. The presence of diagnosed comorbidities that can be confused with or can exacerbate&#xD;
             the condition- to be assessed by X-ray - including but not limited to:&#xD;
&#xD;
               -  Calcaneal stress fracture&#xD;
&#xD;
               -  Suspected partial thickness tear of the Achilles tendon, as assessed by the&#xD;
                  investigator&#xD;
&#xD;
               -  Calcaneal tumor&#xD;
&#xD;
               -  Tarsal tunnel syndrome (diagnosed)&#xD;
&#xD;
               -  Significant bone deformity of the foot that may interfere with the study&#xD;
&#xD;
          7. The presence of diagnosed comorbidities that require surgery or are unlikely to&#xD;
             improve - to be assessed by Investigator-including but not limited to:&#xD;
&#xD;
               -  Nerve entrapment syndrome&#xD;
&#xD;
               -  Acute traumatic rupture of the Achilles tendon&#xD;
&#xD;
               -  Partial thickness tears of the Achilles Tendon&#xD;
&#xD;
          8. Affected site exhibits clinical signs and symptoms of infection&#xD;
&#xD;
          9. Known allergy or known sensitivity to Aminoglycosides&#xD;
&#xD;
         10. Subjects who are non-ambulatory&#xD;
&#xD;
         11. History of more than 14 days of treatment with immune-suppressants (including systemic&#xD;
             corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who&#xD;
             are anticipated to require such medications during the course of the study&#xD;
&#xD;
         12. Prior radiation at the site&#xD;
&#xD;
         13. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding&#xD;
             enrollment&#xD;
&#xD;
         14. Immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia,&#xD;
             Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV) or Lyme&#xD;
             disease&#xD;
&#xD;
         15. History of any conditions (including drug or alcohol abuse, medical or psychiatric&#xD;
             condition) that is likely to impair understanding of or compliance with the study&#xD;
             protocol, in the judgment of the investigator&#xD;
&#xD;
         16. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women&#xD;
             of childbearing potential who are planning to become pregnant during the time of the&#xD;
             study OR are unwilling/unable to use acceptable methods of contraception (birth&#xD;
             control pills, barriers, or abstinence)&#xD;
&#xD;
         17. Workers' compensation patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Union Memorial Hospital Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILD Research Center</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Five Cities Foot Clinic</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Veterans Affairs</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Podiatry</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Center of Illinois</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot &amp; Ankle Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Podiatry, Inc.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Achilles Tendonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

